Pieris Pharmaceuticals, Inc. (NASDAQ:PIRS) has been given an average broker rating score of 1.00 (Strong Buy) from the one brokers that cover the company, Zacks Investment Research reports. One analyst has rated the stock with a strong buy rating.
Analysts have set a 1-year consensus price objective of $8.50 for the company and are expecting that the company will post ($0.13) EPS for the current quarter, according to Zacks. Zacks has also assigned Pieris Pharmaceuticals an industry rank of 147 out of 265 based on the ratings given to its competitors.
Shares of Pieris Pharmaceuticals (NASDAQ:PIRS) opened at 2.15 on Friday. The company’s 50 day moving average price is $1.89 and its 200 day moving average price is $1.67. Pieris Pharmaceuticals has a 12 month low of $1.30 and a 12 month high of $2.48. The stock’s market capitalization is $92.57 million.
Hedge funds have recently bought and sold shares of the company. Sabby Management LLC boosted its stake in Pieris Pharmaceuticals by 823.4% in the second quarter. Sabby Management LLC now owns 1,615,992 shares of the company’s stock worth $2,602,000 after buying an additional 1,440,992 shares during the last quarter. Lombard Odier Asset Management USA Corp boosted its stake in Pieris Pharmaceuticals by 20.3% in the second quarter. Lombard Odier Asset Management USA Corp now owns 3,166,915 shares of the company’s stock worth $5,099,000 after buying an additional 533,965 shares during the last quarter. Finally, BVF Inc. IL boosted its stake in Pieris Pharmaceuticals by 321.2% in the third quarter. BVF Inc. IL now owns 1,016,593 shares of the company’s stock worth $1,858,000 after buying an additional 775,241 shares during the last quarter. 47.58% of the stock is owned by institutional investors.
“Brokerages Expect Pieris Pharmaceuticals, Inc. (PIRS) to Post ($0.13) Earnings Per Share” was first reported by sleekmoney and is the sole property of of sleekmoney. If you are reading this piece on another site, it was stolen and reposted in violation of US & international copyright and trademark legislation. The legal version of this piece can be accessed at http://sleekmoney.com/brokerages-expect-pieris-pharmaceuticals-inc-pirs-to-post-0-13-earnings-per-share/1661503.html.
About Pieris Pharmaceuticals
Pieris Pharmaceuticals, Inc is a clinical-stage biopharmaceutical company. The Company’s pipeline includes immuno-oncology multi-specifics tailored for the tumor micro-environment, an inhaled Anticalin to treat uncontrolled asthma and a half-life-optimized Anticalin to treat anemia. Its Anticalins proteins are a class of low molecular-weight therapeutic proteins derived from lipocalins, which are naturally occurring low-molecular weight human proteins typically found in blood plasma and other bodily fluids.
For more information about research offerings from Zacks Investment Research, visit Zacks.com
This story was originally published by sleekmoney (http://sleekmoney.com) and is the sole property of sleekmoney. If you are reading this article on another website, that means this article was illegally copied and re-published to this website in violation of U.S. and International copyright law. You can view the original version of this story at http://sleekmoney.com/brokerages-expect-pieris-pharmaceuticals-inc-pirs-to-post-0-13-earnings-per-share/1661503.html
Receive News & Ratings for Pieris Pharmaceuticals Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Pieris Pharmaceuticals Inc. and related companies with MarketBeat.com's FREE daily email newsletter.